Skip to main content
. 2014 Feb 24;14:125. doi: 10.1186/1471-2407-14-125

Table 2.

Immunohistochemical staining for primary tumors and metastatic site

  Wnt3a Wnt5a β-catenin MMP-9 VEGFR-2
Primary tumor
51 (61.4%)
58 (69.9%)
70 (84.3%)
45 (54.2%)
30 (36.1%)
Metastatic site
38 (45.8%)
39 (47.0%)
44 (53.0%)
28 (33.7%)
22 (26.5%)
Concordance rate 79.4% 76.2% 79.4% 68.3% 40.0%